Ingenol mebutate

Drug Profile

Ingenol mebutate

Alternative Names: 3-Ingenyl angelate; I3A; Ingenol-3-angelate; PEP-005; PEP005-015; Picato

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator National Cancer Institute (USA)
  • Developer LEO Pharma; Peplin
  • Class Antineoplastics; Ingenols; Macrocyclic compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunostimulants; Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Actinic keratosis
  • Phase II Warts
  • No development reported Basal cell cancer; Bladder cancer; Leukaemia; Squamous cell cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Bladder-cancer in Australia (Intravesicular)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Leukaemia in Australia (IV)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Warts in USA (Topical, Gel)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top